At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,366 enrolled
Drug / intervention
Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) 0.5 mL by Intramuscular Injection
Wyeth is now a wholly owned subsidiary of Pfizer·observational·Posted May 23, 2008·Updated Nov 16, 2010
In Brief
An observational study evaluating Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) for Vaccines, Pneumococcal Conjugate Vaccine. Completed, enrolled 3,366 participants across 1 site.
Detailed Summary
To collect post-marketing information on the safety of Prevenar in Filipino patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsVaccines, Pneumococcal Conjugate Vaccine
CountriesPhilippines
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedMay 23, 2008
Enrollment StartApr 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.1 years ago
Interventions
Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)biological